StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Perioperative celecoxib, combined with opioids, is an effective and safe regimen for pain control in TKA patients. Perioperative celecoxib can significantly decrease postoperative pain scores at ...

Background: Conceptualisation and classification of functional disorders appear highly inconsistent in the health-care system, particularly in primary care. Numerous terms and overlapping ...